Oral biopharmaceutics tools - Time for a new initiative - An introduction to the IMI project OrBiTo

European Journal of Pharmaceutical Sciences

Volumn 57, Issue 1, 2014, Pages 292-299

  Lennernas H ^a   Aarons, L ^b   Augustijns, P ^c   Beato, S ^d   Bolger, M ^e   Box, K ^d   Brewster, M ^d   Butler, J ^f   Dressman, J ^g   Holm, R ^h   Julia Frank, K ⁱ   Kendall, R ^j   Langguth, P ^k   Sydor, J ^l   Lindahl, A ^m   McAllister, M ⁿ   Muenster, U ^o   Mullertz A ^p   Ojala, K ^d   Pepin, X ^q   Reppas, C ^r   Rostami Hodjegan, A ^b   Verwei, M ^s   Weitschies, W ^t   Wilson, C ^u   Karlsson, C ^v   Abrahamsson, B ^v   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Novartis ^*  (Finland)

^e Simulations Plus Inc   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g GOETHE UNIVERSITY   (Germany)

^h H LUNDBECK A S   (Denmark)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j Merck Sharp & Dohme Limited   (United Kingdom)

^k JOHANNES GUTENBERG UNIVERSITY   (Germany)

^l ABBVIE INC   (United States)

^m MEDICAL PRODUCTS AGENCY   (Sweden)

ⁿ PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^o BAYER PHARMA AG   (Germany)

^p UNIVERSITY OF COPENHAGEN   (Denmark)

^q SANOFI   (France)

^r UNIVERSITY OF ATHENS   (Greece)

^s TNO   (Netherlands)

^t UNIVERSITY OF GREIFSWALD   (Germany)

^u UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^v ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

BCS; Dissolution; Drug absorption; IVIVC; PBPK; Permeability

Indexed keywords

ACTIVE TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRODUCT DEVELOPMENT; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; GASTROINTESTINAL TRACT; MEDICINAL CHEMISTRY; METABOLISM; PERMEABILITY; PHARMACEUTICS; PHARMACOKINETICS; PROCEDURES; PROGRAM DEVELOPMENT; SOLUBILITY;

DRUG; DRUG DOSAGE FORM;

ADMINISTRATION, ORAL; ANIMALS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DOSAGE FORMS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROGRAM DEVELOPMENT; SOLUBILITY;

EID: 84899666320     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.10.012     Document Type: Review

References (33)

1. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Deliv Rev. 50 Suppl. 1 2001 S41 S67
2. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
3. P. Artursson Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells J. Pharm. Sci. 79 1990 476 482
4. L. Bønløkke, L. Hovgaard, H.G. Kristensen, L. Knutson, A. Lindahl, and H. Lennernäs A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans Eur. J. Pharm. Sci. 8 1999 19 27
5. L. Bønløkke, L. Hovgaard, H.G. Kristensen, L. Knutson, and H. Lennernäs Direct estimationof the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans Eur. J. Pharm. Sci. 12 2001 239 250
6. George E.P. Box, and Norman R. Draper Empirical Model-Building and Response Surfaces 1987 Wiley p. 424
7. T. Buckley, S.M. Fischer, G. Fricker, and M. Brandl In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives Eur. J. Pharm. Sci. 45 2012 235 250
8. J.M. Butler, and J.B. Dressman The developability classification system: application of biopharmaceutics concepts to formulation development J. Pharm. Sci. 99 2010 4940 4954
9. M.-L. Chen, G.L. Amidon, L.Z. Benet, H. Lennernas, and L.X. Yu The BCS, BDDCS, and regulatory guidances Pharm. Res. 28 2011 1774 1778
10. P.A. Dickinson, W.W. Lee, P.W. Stott, A.I. Townsend, J.P. Smart, P. Ghahramani, T. Hammett, L. Billett, S. Behn, R.C. Gibb, and B. Abrahamsson Clinical relevance of dissolution testing in quality by design AAPS J. 10 2008 380 390
11. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 11 Suppl 2 2000 S73 S80
12. J.B. Dressman, G.L. Amidon, C. Reppas, and V.P. Shah Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms Pharm. Res. 15 1998 11 22
13. J.B. Dressman, K. Thelen, and S. Willmann An update on computational oral absorption simulation Exp. Opin. Drug Metab. Toxicol. 7 2011 1345 1364
14. S.M. Huang, D.R. Abernethy, Y. Wang, P. Zhao, and I. Zineh The utility of modeling and simulation in drug development and regulatory review J. Pharm. Sci. 2013 24 doi: 10.1002/jps.23570
15. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline Pharmaceutical Development Q8(R2), August 2009.
16. M. Jamei, D. Turner, J. Yang, S. Neuhoff, S. Polak, A. Rostami-Hodjegan, and G. Tucker Population-based mechanistic prediction of oral drug absorption AAPS J. 11 2009 225 237
17. L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J.B. Dressman, and C. Reppas Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies Pharm. Res. 23 2006 165 176
18. H. Kortejarvi, A. Urtti, and M. Yliperttula Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates Eur. J. Pharm. Sci. 30 2007 155 166
19. C.A. Larregieu, and L.Z. Benet Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements AAPS J. 15 2013 483 497
20. H. Lennernäs Human intestinal permeability: an overview J. Pharm. Sci. 87 1998 403 410
21. H. Lennernas, and B. Abrahamsson The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J. Pharm. Pharmacol. 57 2005 273 285
22. H. Lennernas, K. Palm, U. Fagerholm, and P. Artursson Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo Int. J. Pharm. 127 1996 103 107
23. A. Lindahl, A.-L. Ungell, and H. Lennernäs Characterisation of fluids from the human stomach and proximal jejunum in the fasted state Pharm. Res. 14 1997 497 502
24. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249
25. B.L. Pedersen, H. Brøndsted, H. Lennernäs, F.N. Christensen, A. Müllertz, and H.G. Kristensen Dissolution of hydrocortisone in human and simulated intestinal fluids Pharm. Res. 17 2000 183 189
26. P. Poulin, R.D.O. Jones, H.M. Jones, C.R. Gibson, M. Rowland, and J.Y. Chien et al. Pharmacokinetics part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach J. Pharm. Sci. 100 2011 4127 4157
27. M. Rowland, and T.N. Tozer Clinical Pharmacokinetics: Concepts and Applications third ed. 1995 Williams & Wilkins Philadelphia pp. 119-134, (chapter 9)
28. D.A. Smith Evolution of ADME science: Where else can modeling and simulation contribute? Mol. Pharm. 10 2013 1162 1170
29. D. Sun, H. Lennernas, L.S. Welage, J.L. Barnett, C.P. Landowski, D. Foster, D. Fleisher, K.D. Lee, and G.L. Amidon Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs Pharm. Res. 19 2002 1400 1416
30. Y. Tsume, and G.L. Amidon The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation Mol. Pharm. 7 2010 1235 1243
31. J.D. Wetherington, M. Pfister, C. Banfield, J. Stone, R. Krishna, S. Allerheiligen, and D.M. Grasela Application of pharmacometrics in model-based drug development: strengths, weaknesses, opportunities, and threats for broad J. Clin. Pharmacol. 50 2010 31S 46S
32. H.D. Williams, N.L. Trevaskis, S.A. Charman, R.M. Shanker, W.N. Charman, C.W. Pouton, and C.J. Porter Strategies to address low drug solubility in discovery and development Pharmacol. Rev. 65 2013 315 499
33. P. Zhao, L. Zhang, J.A. Grillo, Q. Liu, J.M. Bullock, Y.J. Moon, P. Song, S.S. Brar, R. Madabushi, T.C. Wu, B.P. Booth, N.A. Rahman, K.S. Reynolds, E. Gil Berglund, L.J. Lesko, and S.M. Huang Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review Clin. Pharmacol. Ther. 89 2011 259 267